On September 22, Amgen rose 4.79% in pre-market trading, trading at $410.27/share, with turnover of $7.4829 million.

On the news front, Amgen announced that its experimental drug Dazodalibep achieved positive topline results in a Phase 3 clinical trial for moderate-to-severe systemic Sjogren's Disease. The study demonstrated a statistically significant and clinically meaningful improvement in systemic disease activity compared to placebo. The additional Oasiz 303 Phase 3 study for moderate-to-severe symptomatic Sjogren's Disease is expected to complete in Q4. Analysts noted that if the drug's success continues through subsequent regulatory stages, its market potential could be substantial, potentially redefining the treatment landscape for Sjogren's Disease.

The positive trial data adds to a string of recent pipeline wins for Amgen. Earlier this month, its Imdelltra in combination with AstraZeneca's Imfinzi met the primary overall survival endpoint in a Phase 3 trial for extensive-stage small cell lung cancer, and the FDA approved reduced monitoring time for Imdelltra's first two doses, reinforcing the company's strengthening R&D momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)